High Flow Oxygen Therapy Devices Market

High Flow Oxygen Therapy Devices Market by Product Type (High Flow Nasal Cannulas, Masks and Tubing, Ventilators, and Standalone High Flow Oxygen Therapy Devices), Modality (Portable and Stationary), Application (Acute Respiratory Failure, Chronic Obstructive Pulmonary Disease (COPD), Heart Failure, and Others), End-User (Hospitals and Clinics, Home Care Settings, Ambulatory Surgical Centers and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of respiratory diseases, expansion of home healthcare and telemedicine, technological advancements in high flow oxygen therapy devices, and increase in product development activities across the globe.

The global high-flow oxygen therapy devices market is estimated to grow at a CAGR of 2.31% during the forecast period from 2025 to 2032. The increasing prevalence of respiratory diseases, such as COPD, asthma, pneumonia, and Acute Respiratory Distress Syndrome (ARDS), is significantly driving the demand for High Flow Oxygen Therapy (HFOT) devices as healthcare systems seek effective non-invasive treatment options. Simultaneously, the expansion of home healthcare and telemedicine is making HFOT more accessible, enabling patients to receive long-term oxygen therapy in home settings, reducing hospital visits, and improving overall patient management. Technological advancements, including the development of portable, AI-integrated, and remote-monitoring-enabled HFOT devices, are further enhancing their adoption by ensuring precision, ease of use, and improved patient outcomes. Additionally, the surge in product development activities across the globe, with key players continuously innovating and launching advanced devices, is expanding the market’s growth potential. Collectively, these factors are fueling the overall HFOT devices market by improving accessibility, efficiency, and effectiveness in respiratory care during the forecast period from 2025 to 2032.

High Flow Oxygen Therapy Devices Market Dynamics:

According to the latest data provided by the Australian Institute of Health and Welfare, in 2022, around 8.5 million (34%) people in Australia were estimated to have chronic respiratory conditions. Additionally, as per the recent data provided by the Global Burden of Disease (2023), approximately, 1 in 20 people globally suffered from chronic respiratory diseases.

Furthermore, according to the recent data and stats provided by the World Health Organization (2024), asthma affects an estimated 262 million people globally. Chronic respiratory disorders alone account for a substantial portion of the global disease burden, with millions of patients requiring continuous oxygen support due to progressive lung function decline. Additionally, the increasing incidence of asthma exacerbations, often triggered by environmental pollutants, allergens, and climate change, has heightened the need for efficient oxygen delivery systems like HFOT, which provide heated, humidified oxygen at high flow rates, improving oxygenation and reducing respiratory distress thereby boosting the overall market of high flow oxygen therapy devices across the globe.

Moreover, the expansion of home healthcare and telemedicine is significantly boosting the market for high-flow oxygen therapy devices, as more patients with chronic respiratory diseases seek non-invasive, efficient oxygen therapy solutions in home settings. The rising prevalence of chronic obstructive pulmonary disease (COPD), asthma, and other respiratory conditions, coupled with the preference for personalized, home-based care, has driven the demand for high-flow oxygen therapy devices that provide heated, humidified oxygen with high flow rates. Technological advancements, including remote patient monitoring, AI-driven oxygen adjustments, and wireless connectivity, are making high flow oxygen therapy devices more accessible for home use, reducing hospital readmissions and improving patient compliance.

For instance, in August 2023, Telesair’s Bonhawa high flow oxygen therapy system received CE Mark approval, highlighting the industry’s focus on developing user-friendly, portable, and telemedicine-compatible devices. Additionally, in July 2024, Owens & Minor, Inc. announced that it had entered into a definitive agreement to acquire Rotech Healthcare Holdings, Inc., a privately held home-based care business headquartered in Orlando, Florida, for $1.36 billion in cash. Rotech is one of the largest providers of home medical equipment and related products and services in the United States, with a comprehensive offering of oxygen therapy devices, other respiratory therapy equipment, wound care equipment and supplies, and diabetes devices and supplies.

Thus, the factors mentioned above are expected to boost the overall market of high flow oxygen therapy devices across the globe during the forecast period from 2025 to 2032.

However, an increase in product recalls and stringent regulatory concerns for product recalls may hinder the future market of high flow oxygen therapy devices during the forecasted period.

High Flow Oxygen Therapy Devices Market Segment Analysis:

High Flow Oxygen Therapy Devices Market by Product Type (High Flow Nasal Cannulas, Masks and Tubing, Ventilators, and Standalone High Flow Oxygen Therapy Devices), Modality (Portable and Stationary), Application (Acute Respiratory Failure, Chronic Obstructive Pulmonary Disease (COPD), Heart Failure, and Others), End-User (Hospitals and Clinics, Home Care Settings, Ambulatory Surgical Centers and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the high flow oxygen therapy devices market, the high flow nasal cannulas segment is expected to hold a significant share in 2024.  High Flow Nasal Cannulas (HFNC) are significantly boosting the overall market for high-flow oxygen therapy devices by offering a more comfortable, efficient, and clinically effective alternative to traditional oxygen therapy methods. Unlike conventional oxygen delivery systems such as face masks and non-rebreather masks, HFNC provides heated and humidified oxygen at high flow rates, which enhances patient compliance and reduces discomfort, particularly for individuals requiring long-term respiratory support. Furthermore, the growing prevalence of chronic respiratory diseases like COPD, pneumonia, acute respiratory distress syndrome (ARDS), and post-COVID-19 complications has driven the demand for high-flow oxygen therapy, with HFNC emerging as a preferred option due to its ability to deliver precise oxygen concentrations while ensuring better airway hydration and clearance of secretions.

Additionally, HFNC plays a crucial role in preventing the need for invasive ventilation, reducing hospital stays, and lowering healthcare costs, which has led to its increasing adoption in emergency departments, intensive care units (ICUs), and home care settings. The rising geriatric population, which is more susceptible to respiratory disorders, has further fueled market growth. Moreover, technological advancements such as portable HFNC devices, integrated monitoring systems, and smart sensors that adjust oxygen flow rates based on patient needs are enhancing the overall effectiveness and ease of use of these devices. For instance, in August 2023, the Intersurgical i-flo™ High Flow Nasal Cannula was verified by the FDA. The i-flo’s unobtrusive design had been developed with a focus on performance and patient comfort and includes several unique features and benefits to help ensure optimal delivery of high-flow oxygen therapy, a significant mode for respiratory support in patients with hypoxemic respiratory failure.

Moreover, as healthcare providers and policymakers emphasize non-invasive ventilation strategies to manage respiratory distress, the HFNC market continues to expand, supported by increasing investments in research, favorable reimbursement policies, and growing awareness about the benefits of high-flow oxygen therapy. With its ability to improve patient outcomes, reduce complications, and offer superior oxygen delivery, HFNC is playing a crucial role in driving the overall growth of the high-flow oxygen therapy device market, making it an indispensable solution for modern respiratory care.

Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of high flow oxygen therapy devices across the globe.

North America is expected to dominate the overall high flow oxygen therapy devices market:

North America is expected to account for the highest proportion of the high flow oxygen therapy devices market in 2024, out of all regions. The region is anticipated to dominate the overall high flow oxygen therapy devices market due to its well-established healthcare infrastructure, high adoption of advanced respiratory care technologies, and a growing patient population with chronic respiratory diseases such as COPD, asthma, and sleep apnea. The increasing prevalence of respiratory infections, including pneumonia and COVID-19, has further driven the demand for high-flow oxygen therapy devices in hospitals, home care settings, and emergency care units. Additionally, favorable reimbursement policies, strong government support, and continuous technological advancements by key market players in the U.S. and Canada are boosting market growth in North America.

According to the recent data and stats provided by the American Lung Association (2024), asthma accounted for 10.8% of females and 6.5% of males across the region of the United States.

As per the data provided by the Centre for Disease Control and Prevention (2024), in 2022, 4.6% of adults had been diagnosed with COPD, emphysema, or chronic bronchitis in the United States. The rising prevalence of asthma and COPD is driving the high-flow oxygen therapy devices market, as these conditions often require continuous oxygen support. COPD, marked by airflow obstruction and hypoxemia, necessitates long-term oxygen therapy, while severe asthma exacerbations also demand high-flow oxygen for stabilization. These devices provide heated, humidified oxygen with adjustable flow rates, improving oxygenation and reducing breathing effort and airway inflammation, making them a preferred choice over traditional oxygen therapy.

Additionally, the integration of artificial intelligence (AI) and the Internet of Things (IoT) in high-flow oxygen therapy devices allows for personalized oxygen delivery, ensuring optimal patient care and reducing complications. Furthermore, advancements in material science have led to the development of lightweight, portable devices, enabling home-based and ambulatory care, which is expanding the adoption of these devices beyond hospital settings. Additionally, the increasing adoption of non-invasive ventilation technologies has further fueled demand for high-flow oxygen therapy devices.

Furthermore, the increasing launch of new high-flow oxygen therapy devices and regulatory product approvals has significantly boosted the overall market by expanding treatment options, improving accessibility, and enhancing technological capabilities. Manufacturers are continuously developing advanced devices with improved features such as better humidification, adjustable oxygen flow rates, enhanced portability, and smart monitoring systems. These innovations cater to the growing demand for efficient and non-invasive respiratory support, particularly for patients suffering from conditions like chronic obstructive pulmonary disease (COPD), acute hypoxemic respiratory failure, and post-COVID-19 complications. For instance, in February 2021, Masimo announced the U.S. launch of softFlow®, an innovative pulmonary care therapy that delivers nasal high-flow warmed and humidified respiratory gases to spontaneously breathing patients. The technology, available on the softFlow 50, provided adult patients with high-flow respiratory support through a soft nasal cannula by generating a consistent flow of warm, humidified air or an air/oxygen mixture.

Thus, the above-mentioned factors are expected to escalate the market of high flow oxygen therapy devices in the region.

High Flow Oxygen Therapy Devices Market Key Players:

Some of the key market players operating in the high flow oxygen therapy devices market include Fisher & Paykel Healthcare, Masimo, Vapotherm, BMC Medical, ResMed, Allied Medical Limited, Hamilton Medical, Neotech Medical Systems Pvt. Ltd., Respircare, Ambulanc (Shenzhen) Tech. Co., Ltd., Intersurgical Ltd., Drägerwerk AG & Co. KGaA, MEKICS Co., Ltd., Peak Medical, Koninklijke Philips N.V., Hamilton Medical, GE Healthcare, Medtronic plc., Mindray, Nihon Kohden, Smiths Medical, and others.

Recent Developmental Activities in the High Flow Oxygen Therapy Devices Market:

• In March 2022, Fisher & Paykel Healthcare Corporation Limited announced that it had released the Airvo 3 high flow oxygen therapy system.

Key Takeaways From the High Flow Oxygen Therapy Devices Market Report Study

• Market size analysis for current high flow oxygen therapy devices size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the high flow oxygen therapy devices market.
• Various opportunities available for the other competitors in the high flow oxygen therapy devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current high flow oxygen therapy devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for high flow oxygen therapy devices market growth in the coming future?

Target Audience Who Can be Benefited From This High Flow Oxygen Therapy Devices Market Report Study

• High flow oxygen therapy device product providers
• Research organizations and consulting companies
• High flow oxygen therapy devices -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in high flow oxygen therapy devices
• Various end-users who want to know more about the high flow oxygen therapy devices market and the latest technological developments in the high flow oxygen therapy devices market. 

Frequently Asked Questions for the High Flow Oxygen Therapy Devices Market:

1. What are high flow oxygen therapy devices?

• High-flow oxygen therapy (HFOT) devices are advanced respiratory support systems that deliver a high flow of heated, humidified oxygen through a nasal cannula. These devices provide precise oxygen concentrations (up to 100%) at flow rates higher than conventional oxygen therapy, typically ranging from 20 to 60 liters per minute. They help in managing conditions like acute respiratory failure, COPD, and post-extubation support by improving oxygenation, reducing the work of breathing, and enhancing patient comfort.

2. What is the market for high flow oxygen therapy devices?

• The global high-flow oxygen therapy devices market is estimated to grow at a CAGR of 2.31% during the forecast period from 2025 to 2032.

3. What are the drivers for the global high flow oxygen therapy devices market?

• The increasing prevalence of respiratory diseases, such as COPD, asthma, pneumonia, and Acute Respiratory Distress Syndrome (ARDS), is significantly driving the demand for High Flow Oxygen Therapy (HFOT) devices as healthcare systems seek effective non-invasive treatment options. Simultaneously, the expansion of home healthcare and telemedicine is making HFOT more accessible, enabling patients to receive long-term oxygen therapy in home settings, reducing hospital visits, and improving overall patient management. Technological advancements, including the development of portable, AI-integrated, and remote-monitoring-enabled HFOT devices, are further enhancing their adoption by ensuring precision, ease of use, and improved patient outcomes. Additionally, the surge in product development activities across the globe, with key players continuously innovating and launching advanced devices, is expanding the market’s growth potential. Collectively, these factors are fueling the overall HFOT devices market by improving accessibility, efficiency, and effectiveness in respiratory care during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global high flow oxygen therapy devices market?

• Some of the key market players operating in the high flow oxygen therapy devices are Fisher & Paykel Healthcare, Masimo, Vapotherm, BMC Medical, ResMed, Allied Medical Limited, Hamilton Medical, Neotech Medical Systems Pvt. Ltd., Respircare, Ambulanc (Shenzhen) Tech. Co., Ltd., Intersurgical Ltd., Drägerwerk AG & Co. KGaA, MEKICS Co., Ltd., Peak Medical, Koninklijke Philips N.V., Hamilton Medical, GE Healthcare, Medtronic plc., Mindray, Nihon Kohden, Smiths Medical, and others.

5. Which region has the highest share in the global high flow oxygen therapy devices market?

• North America is expected to account for the highest proportion of the high flow oxygen therapy devices market in 2024, out of all regions. The region is anticipated to dominate the overall high flow oxygen therapy devices market due to its well-established healthcare infrastructure, high adoption of advanced respiratory care technologies, and a growing patient population with chronic respiratory diseases such as COPD, asthma, and sleep apnea. The increasing prevalence of respiratory infections, including pneumonia and COVID-19, has further driven the demand for high-flow oxygen therapy devices in hospitals, home care settings, and emergency care units. Additionally, favorable reimbursement policies, strong government support, and continuous technological advancements by key market players in the U.S. and Canada are boosting market growth in North America.